The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer Lett 2007 Jan 08;245(1-2):61-8
Date
02/07/2006Pubmed ID
16458430Pubmed Central ID
PMC1741855DOI
10.1016/j.canlet.2005.12.026Scopus ID
2-s2.0-33845624102 (requires institutional sign-in at Scopus site) 50 CitationsAbstract
We evaluated the association between the XPD exon 10 Asp(312)Asn and exon 23 Lys(751)Gln polymorphisms and the risk of pancreatic cancer in a hospital-based study of 344 patients and 386 controls frequency matched by age, gender, and race. Stratified analyses showed ever smokers carrying the Asn(312)Asn genotype had a significantly reduced risk when compared with those carrying the (312)Asp allele (OR=0.46, 95% confidence interval 0.24-0.88) (P for interaction=0.03). The (312)Asp-(751)Gln was identified as the putative at risk haplotype. Our study shows that the XPD gene polymorphism could be a genetic risk modifier for smoking-related pancreatic cancer.
Author List
Jiao L, Hassan MM, Bondy ML, Abbruzzese JL, Evans DB, Li DAuthor
Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenocarcinomaAged
Amino Acid Substitution
Asparagine
Aspartic Acid
Carcinoma, Pancreatic Ductal
Case-Control Studies
Female
Gene Frequency
Genotype
Glutamine
Haplotypes
Humans
Linkage Disequilibrium
Lysine
Male
Middle Aged
Pancreatic Neoplasms
Polymorphism, Single Nucleotide
Risk Factors
Smoking
Xeroderma Pigmentosum Group D Protein
